The central conserved region (CCR) of respiratory syncytial virus (RSV) G protein modulates host miRNA expression and alters the cellular response to infection

Vaccines

Volumn 5, Issue 3, 2017, Pages

  Bakre, Abhijeet A ^a   Harcourt, Jennifer L ^b   Haynes, Lia M ^b   Anderson, Larry J ^c   Tripp, Ralph A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CX3CR1; IFN ; MicroRNAs; Respiratory syncytial virus; RSV

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 29; MICRORNA; MICRORNA 24; MICRORNA 26B; MICRORNA 337; MICRORNA 520A; RNA 18S; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ELECTRIC RESISTANCE; GENE EXPRESSION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; POINT MUTATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UPREGULATION; VIRAL PLAQUE ASSAY; VIRUS INFECTIVITY; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 85024390428     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines5030016     Document Type: Article

References (78)

1. Shay, D.K.; Holman, R.C.; Newman, R.D.; Liu, L.L.; Stout, J.W.; Anderson, L.J. Bronchiolitis-associated hospitalizations among us children, 1980–1996. JAMA 1999, 282, 1440–1446. [CrossRef] [PubMed]
2. Stockman, L.J.; Curns, A.T.; Anderson, L.J.; Fischer-Langley, G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the united states, 1997–2006. Pediatr. Infect. Dis. J. 2012, 31, 5–9. [CrossRef] [PubMed]
3. Zhou, H.; Thompson, W.W.; Viboud, C.G.; Ringholz, C.M.; Cheng, P.Y.; Steiner, C.; Abedi, G.R.; Anderson, L.J.; Brammer, L.; Shay, D.K. Hospitalizations associated with influenza and respiratory syncytial virus in the united states, 1993–2008. Clin. Infect. Dis. 2012, 54, 1427–1436. [CrossRef] [PubMed]
4. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus activity—United States, July 2007–December 2008. MMWR Morb. Mortal. Wkly. Rep. 2008, 57, 1355–1358.
5. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus activity—United States, July 2011–January 2013. MMWR Morb. Mortal. Wkly. Rep. 2013, 62, 141–144.
6. Nair, H.; Nokes, D.J.; Gessner, B.D.; Dherani, M.; Madhi, S.A.; Singleton, R.J.; O’Brien, K.L.; Roca, A.; Wright, P.F.; Bruce, N.; et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010, 375, 1545–1555. [CrossRef]
7. Chin, J.; Magoffin, R.L.; Shearer, L.A.; Schieble, J.H.; Lennette, E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 1969, 89, 449–463. [CrossRef] [PubMed]
8. Weibel, R.E.; Stokes, J., Jr.; Leagus, M.B.; Mascoli, C.C.; Hilleman, M.R. Respiratory virus vaccines. V. Field evaluation for efficacy of heptavalent vaccine. Am. Rev. Respir. Dis. 1966, 94, 362–379. [PubMed]
9. Lindell, D.M.; Morris, S.B.; White, M.P.; Kallal, L.E.; Lundy, P.K.; Hamouda, T.; Baker, J.R., Jr.; Lukacs, N.W. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without th2 associated vaccine-enhanced disease. PLoS ONE 2011, 6, e21823. [CrossRef] [PubMed]
10. Connors, M.; Collins, P.L.; Firestone, C.Y.; Murphy, B.R. Respiratory syncytial virus (rsv) f, g, m2 (22k), and n proteins each induce resistance to rsv challenge, but resistance induced by m2 and n proteins is relatively short-lived. J. Virol. 1991, 65, 1634–1637. [PubMed]
11. Stott, E.J.; Taylor, G.; Ball, L.A.; Anderson, K.; Young, K.K.; King, A.M.; Wertz, G.W. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 1987, 61, 3855–3861. [PubMed]
12. Anderson, L.J.; Dormitzer, P.R.; Nokes, D.J.; Rappuoli, R.; Roca, A.; Graham, B.S. Strategic priorities for respiratory syncytial virus (rsv) vaccine development. Vaccine 2013, 31 (Suppl. 2), B209–B215. [CrossRef] [PubMed]
13. Castilow, E.M.; Varga, S.M. Overcoming t cell-mediated immunopathology to achieve safe rsv vaccination. Future Virol. 2008, 3, 445–454. [CrossRef] [PubMed]
14. Nokes, J.D.; Cane, P.A. New strategies for control of respiratory syncytial virus infection. Curr. Opin. Infect. Dis. 2008, 21, 639–643. [CrossRef] [PubMed]
15. Olson, M.R.; Varga, S.M. Pulmonary immunity and immunopathology: Lessons from respiratory syncytial virus. Expert Rev. Vaccines 2008, 7, 1239–1255. [CrossRef] [PubMed]
16. Power, U.F. Respiratory syncytial virus (rsv) vaccines–two steps back for one leap forward. J. Clin. Virol. 2008, 41, 38–44. [CrossRef] [PubMed]
17. Hendricks, D.A.; Baradaran, K.; McIntosh, K.; Patterson, J.L. Appearance of a soluble form of the g protein of respiratory syncytial virus in fluids of infected cells. J. Gen. Virol. 1987, 68 (Pt 6), 1705–1714. [CrossRef] [PubMed]
18. Roberts, S.R.; Lichtenstein, D.; Ball, L.A.; Wertz, G.W. The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein g are synthesized from alternative initiation codons. J. Virol. 1994, 68, 4538–4546. [PubMed]
19. Gorman, J.J.; Ferguson, B.L.; Speelman, D.; Mills, J. Determination of the disulfide bond arrangement of human respiratory syncytial virus attachment (g) protein by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Protein Sci. 1997, 6, 1308–1315. [CrossRef] [PubMed]
20. Tripp, R.A.; Jones, L.P.; Haynes, L.M.; Zheng, H.; Murphy, P.M.; Anderson, L.J. Cx3c chemokine mimicry by respiratory syncytial virus g glycoprotein. Nat. Immunol. 2001, 2, 732–738. [CrossRef] [PubMed]
21. Johnson, S.M.; McNally, B.A.; Ioannidis, I.; Flano, E.; Teng, M.N.; Oomens, A.G.; Walsh, E.E.; Peeples, M.E. Respiratory syncytial virus uses cx3cr1 as a receptor on primary human airway epithelial cultures. PLoS Pathog. 2015, 11, e1005318. [CrossRef] [PubMed]
22. Chirkova, T.; Lin, S.; Oomens, A.G.; Gaston, K.A.; Boyoglu-Barnum, S.; Meng, J.; Stobart, C.C.; Cotton, C.U.; Hartert, T.V.; Moore, M.L.; et al. Cx3cr1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J. Gen. Virol. 2015, 96, 2543–2556. [CrossRef] [PubMed]
23. Chirkova, T.; Boyoglu-Barnum, S.; Gaston, K.A.; Malik, F.M.; Trau, S.P.; Oomens, A.G.; Anderson, L.J. Respiratory syncytial virus g protein cx3c motif impairs human airway epithelial and immune cell responses. J. Virol. 2013, 87, 13466–13479. [CrossRef] [PubMed]
24. Harcourt, J.; Alvarez, R.; Jones, L.P.; Henderson, C.; Anderson, L.J.; Tripp, R.A. Respiratory syncytial virus g protein and g protein cx3c motif adversely affect cx3cr1+ t cell responses. J. Immunol. 2006, 176, 1600–1608. [CrossRef] [PubMed]
25. Tripp, R.A.; Dakhama, A.; Jones, L.P.; Barskey, A.; Gelfand, E.W.; Anderson, L.J. The g glycoprotein of respiratory syncytial virus depresses respiratory rates through the cx3c motif and substance p. J. Virol. 2003, 77, 6580–6584. [CrossRef] [PubMed]
26. Haynes, L.M.; Caidi, H.; Radu, G.U.; Miao, C.; Harcourt, J.L.; Tripp, R.A.; Anderson, L.J. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (rsv) g protein mediates viral clearance and reduces the pathogenesis of rsv infection in balb/c mice. J. Infect. Dis. 2009, 200, 439–447. [CrossRef] [PubMed]
27. Johnson, C.H.; Miao, C.; Blanchard, E.G.; Caidi, H.; Radu, G.U.; Harcourt, J.L.; Haynes, L.M. Effect of chemokine receptor cx3cr1 deficiency in a murine model of respiratory syncytial virus infection. Comp. Med. 2012, 62, 14–20. [PubMed]
28. Boyoglu-Barnum, S.; Todd, S.O.; Chirkova, T.; Barnum, T.R.; Gaston, K.A.; Haynes, L.M.; Tripp, R.A.; Moore, M.L.; Anderson, L.J. An anti-g protein monoclonal antibody treats rsv disease more effectively than an anti-f monoclonal antibody in balb/c mice. Virology 2015, 483, 117–125. [CrossRef] [PubMed]
29. Jeong, K.I.; Piepenhagen, P.A.; Kishko, M.; DiNapoli, J.M.; Groppo, R.P.; Zhang, L.; Almond, J.; Kleanthous, H.; Delagrave, S.; Parrington, M. Cx3cr1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a g protein-dependent manner. PLoS ONE 2015, 10, e0130517. [CrossRef] [PubMed]
30. Boyoglu-Barnum, S.; Gaston, K.A.; Todd, S.O.; Boyoglu, C.; Chirkova, T.; Barnum, T.R.; Jorquera, P.; Haynes, L.M.; Tripp, R.A.; Moore, M.L.; et al. A respiratory syncytial virus (rsv) anti-g protein f(ab')2 monoclonal antibody suppresses mucous production and breathing effort in rsv ra2-line19f-infected balb/c mice. J. Virol. 2013, 87, 10955–10967. [CrossRef] [PubMed]
31. Harcourt, J.L.; Karron, R.A.; Tripp, R.A. Anti-g protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of g protein cx3c-cx3cr1 binding and leukocyte chemotaxis. J. Infect. Dis. 2004, 190, 1936–1940. [CrossRef] [PubMed]
32. Zhang, W.; Choi, Y.; Haynes, L.M.; Harcourt, J.L.; Anderson, L.J.; Jones, L.P.; Tripp, R.A. Vaccination to induce antibodies blocking the cx3c-cx3cr1 interaction of respiratory syncytial virus g protein reduces pulmonary inflammation and virus replication in mice. J. Virol. 2010, 84, 1148–1157. [CrossRef] [PubMed]
33. Grantham, M.L.; Wu, W.H.; Lalime, E.N.; Lorenzo, M.E.; Klein, S.L.; Pekosz, A. Palmitoylation of the influenza a virus m2 protein is not required for virus replication in vitro but contributes to virus virulence. J. Virol. 2009, 83, 8655–8661. [CrossRef] [PubMed]
34. Hsu, A.C.; Parsons, K.; Barr, I.; Lowther, S.; Middleton, D.; Hansbro, P.M.; Wark, P.A. Critical role of constitutive type i interferon response in bronchial epithelial cell to influenza infection. PLoS ONE 2012, 7, e32947. [CrossRef] [PubMed]
35. Saedisomeolia, A.; Wood, L.G.; Garg, M.L.; Gibson, P.G.; Wark, P.A. Lycopene enrichment of cultured airway epithelial cells decreases the inflammation induced by rhinovirus infection and lipopolysaccharide. J. Nutr. Biochem. 2009, 20, 577–585. [CrossRef] [PubMed]
36. Yoshikawa, T.; Hill, T.; Li, K.; Peters, C.J.; Tseng, C.T. Severe acute respiratory syndrome (sars) coronavirus-induced lung epithelial cytokines exacerbate sars pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J. Virol. 2009, 83, 3039–3048. [CrossRef] [PubMed]
37. Yoshikawa, T.; Hill, T.E.; Yoshikawa, N.; Popov, V.L.; Galindo, C.L.; Garner, H.R.; Peters, C.J.; Tseng, C.T. Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection. PLoS ONE 2010, 5, e8729. [CrossRef] [PubMed]
38. Grainger, C.I.; Greenwell, L.L.; Lockley, D.J.; Martin, G.P.; Forbes, B. Culture of calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm. Res. 2006, 23, 1482–1490. [CrossRef] [PubMed]
39. Harcourt, J.L.; Caidi, H.; Anderson, L.J.; Haynes, L.M. Evaluation of the calu-3 cell line as a model of in vitro respiratory syncytial virus infection. J. Virol. Methods 2011, 174, 144–149. [CrossRef] [PubMed]
40. Couch, R.B.; Englund, J.A.; Whimbey, E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am. J. Med. 1997, 102, 2–9, discussion 25–26. [CrossRef]
41. Dakhama, A.; Vitalis, T.Z.; Hegele, R.G. Persistence of respiratory syncytial virus (rsv) infection and development of rsv-specific igg1 response in a guinea-pig model of acute bronchiolitis. Eur. Respir. J. 1997, 10, 20–26. [CrossRef] [PubMed]
42. Hegele, R.G.; Hayashi, S.; Bramley, A.M.; Hogg, J.C. Persistence of respiratory syncytial virus genome and protein after acute bronchiolitis in guinea pigs. Chest 1994, 105, 1848–1854. [CrossRef] [PubMed]
43. Isaia, G.; Teodosiu, O.; Popescu, G.; Athanasiu, P.; Sternberg, I.; Dumitriu, Z. Persistence of viruses in the nasopharynx of apparently healthy children aged 0–5 years. Results of investigations performed in 1982–83. Virologie 1985, 36, 175–179. [PubMed]
44. Mejias, A.; Chavez-Bueno, S.; Gomez, A.M.; Somers, C.; Estripeaut, D.; Torres, J.P.; Jafri, H.S.; Ramilo, O. Respiratory syncytial virus persistence: Evidence in the mouse model. Pediatr. Infect. Dis. J. 2008, 27, S60–S62. [CrossRef] [PubMed]
45. Sikkel, M.B.; Quint, J.K.; Mallia, P.; Wedzicha, J.A.; Johnston, S.L. Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr. Infect. Dis. J. 2008, 27, S63–S70. [CrossRef] [PubMed]
46. Zhang, L.; Peeples, M.E.; Boucher, R.C.; Collins, P.L.; Pickles, R.J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J. Virol. 2002, 76, 5654–5666. [CrossRef] [PubMed]
47. Harcourt, J.L.; Haynes, L.M. Establishing a liquid-covered culture of polarized human airway epithelial calu-3 cells to study host cell response to respiratory pathogens in vitro. J. Vis. Exp. JoVE 2013. [CrossRef] [PubMed]
48. Teng, M.N.; Whitehead, S.S.; Collins, P.L. Contribution of the respiratory syncytial virus g glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001, 289, 283–296. [CrossRef] [PubMed]
49. Whitehead, S.S.; Juhasz, K.; Firestone, C.Y.; Collins, P.L.; Murphy, B.R. Recombinant respiratory syncytial virus (rsv) bearing a set of mutations from cold-passaged rsv is attenuated in chimpanzees. J. Virol. 1998, 72, 4467–4471. [PubMed]
50. Kim, Y.K.; Choi, E.H.; Lee, H.J. Genetic variability of the fusion protein and circulation patterns of genotypes of the respiratory syncytial virus. J. Med. Virol. 2007, 79, 820–828. [CrossRef] [PubMed]
51. Caidi, H.; Harcourt, J.L.; Tripp, R.A.; Anderson, L.J.; Haynes, L.M. Combination therapy using monoclonal antibodies against respiratory syncytial virus (rsv) g glycoprotein protects from rsv disease in balb/c mice. PLoS ONE 2012, 7, e51485. [CrossRef] [PubMed]
52. Sullender, W. Antigenic analysis of chimeric and truncated g proteins of respiratory syncytial virus. Virology 1995, 209, 70–79. [CrossRef] [PubMed]
53. Bustin, S.A.; Benes, V.; Garson, J.A.; Hellemans, J.; Huggett, J.; Kubista, M.; Mueller, R.; Nolan, T.; Pfaffl, M.W.; Shipley, G.L.; et al. The miqe guidelines: Minimum information for publication of quantitative real-time pcr experiments. Clin. Chem. 2009, 55, 611–622. [CrossRef] [PubMed]
54. Pezzulo, A.A.; Starner, T.D.; Scheetz, T.E.; Traver, G.L.; Tilley, A.E.; Harvey, B.G.; Crystal, R.G.; McCray, P.B., Jr.; Zabner, J. The air-liquid interface and use of primary cell cultures are important to recapitulate the transcriptional profile of in vivo airway epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300, L25–L31. [CrossRef] [PubMed]
55. Mastrangelo, P.; Hegele, R.G. Rsv fusion: Time for a new model. Viruses 2013, 5, 873–885. [CrossRef] [PubMed]
56. Rezaee, F.; DeSando, S.A.; Ivanov, A.I.; Chapman, T.J.; Knowlden, S.A.; Beck, L.A.; Georas, S.N. Sustained protein kinase d activation mediates respiratory syncytial virus-induced airway barrier disruption. J. Virol. 2013, 87, 11088–11095. [CrossRef] [PubMed]
57. Thevenet, P.; Shen, Y.; Maupetit, J.; Guyon, F.; Derreumaux, P.; Tuffery, P. Pep-fold: An updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res. 2012, 40, W288–W293. [CrossRef] [PubMed]
58. Oshansky, C.M.; Krunkosky, T.M.; Barber, J.; Jones, L.P.; Tripp, R.A. Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type i interferon response to infection by a toll-like receptor pathway. Viral Immunol. 2009, 22, 147–161. [CrossRef] [PubMed]
59. Bakre, A.; Mitchell, P.; Coleman, J.K.; Jones, L.P.; Saavedra, G.; Teng, M.; Tompkins, S.M.; Tripp, R.A. Respiratory syncytial virus modifies micrornas regulating host genes that affect virus replication. J. Gen. Virol. 2012, 93, 2346–2356. [CrossRef] [PubMed]
60. Melendi, G.A.; Bridget, D.; Monsalvo, A.C.; Laham, F.F.; Acosta, P.; Delgado, M.F.; Polack, F.P.; Irusta, P.M. Conserved cysteine residues within the attachment g glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic t-lymphocyte responses. Virus Genes 2011, 42, 46–54. [CrossRef] [PubMed]
61. Simard, C.; Nadon, F.; Seguin, C.; Thien, N.N.; Binz, H.; Basso, J.; Laliberte, J.F.; Trudel, M. Subgroup specific protection of mice from respiratory syncytial virus infection with peptides encompassing the amino acid region 174–187 from the g glycoprotein: The role of cysteinyl residues in protection. Vaccine 1997, 15, 423–432. [CrossRef]
62. Haynes, L.M.; Jones, L.P.; Barskey, A.; Anderson, L.J.; Tripp, R.A. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to g glycoprotein cx3c-cx3cr1 interaction and expression of substance p. J. Virol. 2003, 77, 9831–9844. [CrossRef] [PubMed]
63. Li, X.Q.; Fu, Z.F.; Alvarez, R.; Henderson, C.; Tripp, R.A. Respiratory syncytial virus (rsv) infects neuronal cells and processes that innervate the lung by a process involving rsv g protein. J. Virol. 2006, 80, 537–540. [CrossRef] [PubMed]
64. Okabayashi, T.; Kojima, T.; Masaki, T.; Yokota, S.; Imaizumi, T.; Tsutsumi, H.; Himi, T.; Fujii, N.; Sawada, N. Type-iii interferon, not type-i, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res. 2011, 160, 360–366. [CrossRef] [PubMed]
65. Selvaggi, C.; Pierangeli, A.; Fabiani, M.; Spano, L.; Nicolai, A.; Papoff, P.; Moretti, C.; Midulla, F.; Antonelli, G.; Scagnolari, C. Interferon lambda 1–3 expression in infants hospitalized for rsv or hrv associated bronchiolitis. J. Infect. 2014, 68, 467–477. [CrossRef] [PubMed]
66. Villenave, R.; Broadbent, L.; Douglas, I.; Lyons, J.D.; Coyle, P.V.; Teng, M.N.; Tripp, R.A.; Heaney, L.G.; Shields, M.D.; Power, U.F. Induction and antagonism of antiviral responses in respiratory syncytial virus-infected pediatric airway epithelium. J. Virol. 2015, 89, 12309–12318. [CrossRef] [PubMed]
67. Chhabra, R.; Dubey, R.; Saini, N. Cooperative and individualistic functions of the micrornas in the mir-23a~27a~24–2 cluster and its implication in human diseases. Mol. Cancer 2010, 9, 232. [CrossRef] [PubMed]
68. Cao, M.; Seike, M.; Soeno, C.; Mizutani, H.; Kitamura, K.; Minegishi, Y.; Noro, R.; Yoshimura, A.; Cai, L.; Gemma, A. Mir-23a regulates tgf-beta-induced epithelial-mesenchymal transition by targeting e-cadherin in lung cancer cells. Int. J. Oncol. 2012, 41, 869–875. [PubMed]
69. Cheng, A.M.; Byrom, M.W.; Shelton, J.; Ford, L.P. Antisense inhibition of human mirnas and indications for an involvement of mirna in cell growth and apoptosis. Nucleic Acids Res. 2005, 33, 1290–1297. [CrossRef] [PubMed]
70. Bakre, A.; Wu, W.; Hiscox, J.; Spann, K.; Teng, M.N.; Tripp, R.A. Human respiratory syncytial virus non-structural protein ns1 modifies mir-24 expression via transforming growth factor-beta. J. Gen. Virol. 2015, 96, 3179–3191. [CrossRef] [PubMed]
71. Haynes, L.M.; Moore, D.D.; Kurt-Jones, E.A.; Finberg, R.W.; Anderson, L.J.; Tripp, R.A. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol. 2001, 75, 10730–10737. [CrossRef] [PubMed]
72. Kurt-Jones, E.A.; Popova, L.; Kwinn, L.; Haynes, L.M.; Jones, L.P.; Tripp, R.A.; Walsh, E.E.; Freeman, M.W.; Golenbock, D.T.; Anderson, L.J.; et al. Pattern recognition receptors tlr4 and cd14 mediate response to respiratory syncytial virus. Nat. Immunol. 2000, 1, 398–401. [CrossRef] [PubMed]
73. Shingai, M.; Azuma, M.; Ebihara, T.; Sasai, M.; Funami, K.; Ayata, M.; Ogura, H.; Tsutsumi, H.; Matsumoto, M.; Seya, T. Soluble g protein of respiratory syncytial virus inhibits toll-like receptor 3/4-mediated ifn-beta induction. Int. Immunol. 2008, 20, 1169–1180. [CrossRef] [PubMed]
74. Oshansky, C.M.; Barber, J.P.; Crabtree, J.; Tripp, R.A. Respiratory syncytial virus f and g proteins induce interleukin 1alpha, cc, and cxc chemokine responses by normal human bronchoepithelial cells. J. Infect. Dis. 2010, 201, 1201–1207. [CrossRef] [PubMed]
75. Moore, E.C.; Barber, J.; Tripp, R.A. Respiratory syncytial virus (rsv) attachment and nonstructural proteins modify the type i interferon response associated with suppressor of cytokine signaling (socs) proteins and ifn-stimulated gene-15 (isg15). Virol. J. 2008, 5, 116. [CrossRef] [PubMed]
76. Langedijk, J.P.; de Groot, B.L.; Berendsen, H.J.; van Oirschot, J.T. Structural homology of the central conserved region of the attachment protein g of respiratory syncytial virus with the fourth subdomain of 55-kda tumor necrosis factor receptor. Virology 1998, 243, 293–302. [CrossRef] [PubMed]
77. Thornburg, N.J.; Hayward, S.L.; Crowe, J.E., Jr. Respiratory syncytial virus regulates human micrornas by using mechanisms involving beta interferon and nf-kappab. mBio 2012, 3. [CrossRef] [PubMed]
78. Collins, P.L.; Murphy, B.R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc. Am. Thorac. Soc. 2005, 2, 166–173. [CrossRef] [PubMed]